AA
GENB

ALPS Advisors’s Generate Biomedicines GENB Stock Holding History

ALPS Advisors’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
+129,406
New +$1.76M 0.01% 494

Other funds holding GENB

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

ALPS Advisors's GENB Position: Q2 2026 in Review

ALPS Advisors opened a new position in Generate Biomedicines (GENB) in Q2 2026: 129,406 shares worth $2.18M. The stake represents 0.01% of the portfolio and ranks #494 among its holdings.

12 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • ALPS Advisors held 129,406 shares of Generate Biomedicines worth $2.18M as of Q2 2026.
  • Generate Biomedicines was a new ALPS Advisors position in Q2 2026.
  • Generate Biomedicines made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #494 holding.
  • 12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.